Answering the Call in COPD: Practical Strategies for Improving Earlier Diagnosis and Patient-Centered Management in Primary Care – Case Discussion #1

Ver en español

 

 

Tuesday, September 20, 2022
7:30 PM – 8:30 PM CEST
6:30 PM – 7:30 PM BST
1:30 PM – 2:30 PM EDT
PROVIDER STATEMENT

This activity is provided by Integrity Continuing Education, Inc.

This program has been developed in collaboration with International Primary Care Respiratory Group (IPCRG) and COPD Foundation.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

TOPIC

The Role of Combination Therapy in Progressive Exertional Dyspnea

PROGRAM OVERVIEW

Chronic obstructive pulmonary disease (COPD) is a complex and heterogeneous disease that is associated with significant morbidity and mortality. Despite efforts to standardize the diagnosis, treatment, and management of this progressive disease, many patients receive a delayed diagnosis or remain undiagnosed and face dismal outcomes. Additionally, despite the availability of several pharmacologic therapies and continually updated guideline recommendations, COPD is suboptimally treated in current clinical practice. As a result, patients with COPD are associated with a poor quality of life, with many patients living in discomfort and experiencing debilitating exacerbations. Recently, evidence has demonstrated the utility of combination therapy in reducing exacerbations among patients with COPD and updated guidelines have identified specific patient subsets that can benefit from these approaches. Even if appropriate therapy is initiated, patients may have persistent barriers related to optimized medication delivery and adherence. Therefore, individualized evaluation of patient characteristics and associated device selection is recommended. This program will clarify the latest guidelines for the diagnosis, treatment, and management of COPD; provide practical strategies for patients to gain better access to therapy; and focus on informing participants on the utility of recently published evidence and precision medicine-based approaches.

FACULTY

MeiLan Han, MD, MS
Professor of Medicine
Division of Pulmonary and Critical Care
University of Michigan
Ann Arbor, Michigan

John Hurst, PhD, FRCP
Professor of Respiratory Medicine
Department of UCL Respiratory
University College London
Honorary Consultant
Department of Respiratory Medicine
Royal Free London NHS Foundation Trust
London, England

Release date: September 20, 2022
Expiration date: December 20, 2022
Estimated time to complete activity: 1 hour
TARGET AUDIENCE

This educational activity is designed for clinicians working in primary care and family medicine in Europe and worldwide.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants should be able to:

  • Apply evidence-based guidelines to achieve effective screening, prompt diagnosis, accurate assessment, and earlier intervention with the potential to alter the disease course in patients with COPD

  • Employ nonpharmacologic strategies targeting breathlessness to reduce morbidity and mortality in selected patients with COPD

DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of September 20, 2022 through December 20, 2022 participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this Other activity (Twitter-based discussion) for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert AMA PRA Category 1 CreditsTM to an equivalent number of EACCME® credits.

CONTACT INFORMATION

For information about accreditation of this activity, please contact Integrity Continuing Education, Inc. at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any financial relationships with ineligible companies. All identified relevant financial relationships are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. All relevant financial relationships have been mitigated.

The following faculty/planners reported the financial relationships or relationships to products or devices they have with ineligible companies related to the content of these CME activities:

MeiLan Han, MD, MS
Personal fees: Aerogen, Altesa Biopharma, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, DevPro, GlaxoSmithKline, Integrity, Medscape, Merck, Mylan, NACE, Novartis, Polarian, Pulmonx, Regeneron, Sanofi, Teva, United Therapeutics, UpToDate, Verona
In kind research support/funds paid to the institution: American Lung Association, AstraZeneca, Biodesix, Boehringer Ingelheim, COPD Foundation, Gala Therapeutics, NIH, Novartis, Nuvaira, Sanofi, Sunovion
Data Safety Monitoring Board/funds paid to institution: Medtronic, Novartis
Stock options: Altesa Biopharma, Meissa Vaccines

John Hurst, PhD, FRCP
In kind research support/funds paid to the institution: AstraZeneca, Boehringer Ingelheim, Chiesi, Takeda

The Integrity Continuing Education, Inc. planners and managers have no relevant financial relationships with ineligible companies

The IPCRG planners and managers have the following relevant financial relationships with ineligible companies:

Miguel Roman Rodriguez, MD
Advisory Board: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline
Consultant: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline
Speakers’ Bureau: AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Menarini, Pfizer, Teva
Research: AstraZeneca

Ioanna Tsiligianni, MD
Consultant: AstraZeneca, Boehringer Ingelheim, Chiesi, Hellas Pharma, Novartis
Speaker: AstraZeneca, Chiesi, Hellas Pharma
Grants for Educational Activities: AstraZeneca, GlaxoSmithKline, Hellas Pharma

Russell Emeny has no relevant financial relationships with ineligible companies.

The COPD Foundation planners and managers having the following relevant financial relationships with ineligible companies:

Michael W. Hess, MPH, RRT, RPFT
Advisory Board: Boehringer Ingelheim
Consultant: NDD Medical
Speakers’ Bureau: Boehringer Ingelheim, Theravance Biopharma, Viatris
Writer: NDD Medical

Courtney Crim, MD
Consultant: Theravance Biopharma
Employee: GlaxoSmithKline

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. does not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended

For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below:
Click here for more information on minimum system requirements

DISCLAIMER

The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Continue to Pretest